EUVIMEDDescobrir EUVIMED
Open access · CC BY 4.0

ALBI ‐6—A Novel Prognostic Score Combining ALBI and Interleukin‐6 in Patients With HCC Treated With Atezolizumab and Bevacizumab

Paula Bark iD, Lucas Wiesmann iD, Simon Johannes Gairing, Kateryna Shmanko, Lukas Müller iD, Maximilian Moos iD, Fabian Stöhr, Dirk Graafen, Tilman Emrich, Felix Hahn iD, Daniel Pinto Dos Santos, Bernhard Scheiner iD and 20 more

Alimentary Pharmacology & Therapeutics · 2026-10-08

DOI: 10.1111/apt.71012 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, published online on 2026-10-08. Written by Paula Bark and 31 co-authors. Institution: Department of Internal Medicine I, University Medical Centre of the Johannes Gutenberg-University Mainz, Mainz, Germany. Cited 2 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY 4.0).

ResumoSubjectsDados bibliográficosCiteRelated studies

Abstract (original language)

Background/Aims Despite widespread use of combination immunotherapy in advanced liver cancer, reliable biomarkers for baseline risk stratification remain lacking. The inflammatory cytokine interleukin‐6 has established prognostic relevance in this cancer. We investigated the prognostic value of interleukin‐6 and developed a combined score (ALBI‐6) integrating interleukin‐6 with albumin–bilirubin grade, a marker of liver function.

Methods

In this multicentre retrospective cohort study, 216 patients with advanced hepatocellular carcinoma treated with first‐line atezolizumab plus bevacizumab were analysed. Interleukin‐6 was measured at baseline, first response, best response, and progression. The cohort was randomly divided into a training set ( n = 98) and a validation set ( n = 90). ALBI‐6 was derived using Cox regression and evaluated against several established prognostic scores.

Results

Elevated baseline interleukin‐6 was consistently associated with worse overall survival and remained independently prognostic after adjustment for tumour and clinical factors (extrahepatic spread, vascular invasion, alpha‐fetoprotein, performance status, liver function class). In the validation cohort, ALBI‐6 achieved a concordance index of 0.716 and separated patients into three risk groups with significantly different survival (log‐rank p = 0.002); ALBI‐6 was significantly more discriminative than one comparator score (modified albumin–bilirubin grade, p = 0.040), with numerically higher performance than the remaining comparators. In a separate analysis of the full cohort, ALBI‐6 significantly outperformed the CRAFITY score at all assessed time points. Bootstrap validation confirmed model stability.

Conclusions

ALBI‐6 integrates systemic inflammation and liver function into a simple composite index enabling meaningful risk stratification in patients with advanced hepatocellular carcinoma treated with immunotherapy. Prospective external validation is warranted.

Subjects

Author keywords

IL‐6cirrhosishepatocellular carcinomaimmune checkpoint inhibitorsimmunotherapyprognostic scoresystemic therapy

Authors and institutions

  • Department of Internal Medicine I, University Medical Centre of the Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Department of Diagnostic and Interventional Radiology, University Medical Centre of the Johannes Gutenberg-University Mainz, Mainz, Germany.
  • Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Division of Hepatology, Department of Medicine II, University Hospital Wuerzburg, Wuerzburg, Germany.
  • Department of Medicine II, University Hospital, Ludwig Maximilian University Munich, Munich, Germany.
  • Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.

ORCID profiles: Paula Bark, Lucas Wiesmann, Lukas Müller, Maximilian Moos, Felix Hahn, Bernhard Scheiner, Victoria Berit Berger, Matthias Pinter, Florian P Reiter, Najib Ben Khaled, Alexander Philipp, Aurelie Tomczak, Michael T Dill, Beate Katharina Straub, Roman Kloeckner, Arndt Weinmann

Cite

APA

Bark, P., Wiesmann, L., Gairing, S. J., Shmanko, K., Müller, L., Moos, M., Stöhr, F., Graafen, D., Emrich, T., Hahn, F., Dos Santos, D. P., Scheiner, B., Berger, V. B., Pinter, M., Zarka, V., Reiter, F. P., Geier, A., Khaled, N. B., Philipp, A., …, & Foerster, F. (2026). ALBI ‐6—A Novel Prognostic Score Combining ALBI and Interleukin‐6 in Patients With HCC Treated With Atezolizumab and Bevacizumab. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.71012

Vancouver

Bark P, Wiesmann L, Gairing SJ, Shmanko K, Müller L, Moos M, et al. ALBI ‐6—A Novel Prognostic Score Combining ALBI and Interleukin‐6 in Patients With HCC Treated With Atezolizumab and Bevacizumab. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.71012

BibTeX
@article{Bark2026,
  author = {Bark, Paula and Wiesmann, Lucas and Gairing, Simon Johannes and Shmanko, Kateryna and Müller, Lukas and Moos, Maximilian and Stöhr, Fabian and Graafen, Dirk and Emrich, Tilman and Hahn, Felix and Dos Santos, Daniel Pinto and Scheiner, Bernhard and Berger, Victoria Berit and Pinter, Matthias and Zarka, Valentina and Reiter, Florian P and Geier, Andreas and Khaled, Najib Ben and Philipp, Alexander and Springfeld, Christoph and Tomczak, Aurelie and Dill, Michael T and Scholz, Constantin and Mittler, Jens and Lang, Hauke and Straub, Beate Katharina and Kloeckner, Roman and Bäuerle, Tobias and Lange, Christian Markus and Weinmann, Arndt and Galle, Peter Robert and Foerster, Friedrich},
  title = {ALBI ‐6—A Novel Prognostic Score Combining ALBI and Interleukin‐6 in Patients With HCC Treated With Atezolizumab and Bevacizumab},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.71012}
}
Start for free →